These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The experimental and clinical antitumor action of the interferon inducer larifan].
    Author: Gasparian MG, Dzhagatspanian NG, Gevorkian RA, Kamalian LA.
    Journal: Vopr Virusol; 1991; 36(2):127-30. PubMed ID: 1909072.
    Abstract:
    The paper presents the results of experimental and clinical studies on the antitumor effect of larifan. A statistically significant inhibition of growth of some continuous mouse tumors by larifan in a dose of 2.5 mg/kg given for 5-6 days and by a combination of larifan with an immunomodulator, inosiplex, tested on hepatoma XXIIa which has a rather low sensitivity to larifan. The antitumor effect of larifan may be due to interferon production and immunomodulating effect. Treatment with 0.05% larifan ointment of patients with cervical dysplasia of moderate degree resulted in a significant increase of previously diminished production of alpha-interferon after 10-14 vaginal tampons and clinical cure in 88% of cases. A course of 8-10-day larifan monotherapy given before radial therapy resulted in a considerable improvement in patients with cervical cancer of II-III stages, and subsequently, for 1 1/2-month combined radial therapy, no significant changes in production of alpha-IF were observed. At the same time, in patients with cervical cancer treated by radial therapy alone a significant decrease of alpha-IF production by blood mononuclears was observed by the end of therapy.
    [Abstract] [Full Text] [Related] [New Search]